Belantamab is a humanised BCMA-binding antibody, which has been clinically evaluated with the cytotoxic payload MMAF (monomethyl auristatin F) as an ADC for MM therapy (belantamab mafodotin, Blenrep) [24]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.